Novo Nordisk vs. Eli Lilly: Analysts weigh in as the obesity-drug battle heats up
As competition grows in the weight loss drug space, investors are questioning which company will come out on top. Source
Read MoreAs competition grows in the weight loss drug space, investors are questioning which company will come out on top. Source
Read MoreAfter the sell-off in August, markets could have a "recovery rally" in mid-September, before tumbling "another leg lower" and bottoming
Read MoreThe Medicare negotiations are a multi-round process that could produce more savings for taxpayers and seniors and put more pressure
Read MoreIt is a milestone in a controversial process that aims to make costly medications more affordable for older Americans but
Read MoreRo said it hopes its new tool will be able to help patients understand their GLP-1 coverage options so they
Read More"Investors were nervous going in and this print would come as a huge relief," said Mohit Bansal, an analyst at
Read MoreThese are the stocks posting the largest moves in midday trading. Source link
Read MoreEven professional investors use ETFs as a way to get "diversified and easy access to different geographies and themes," wealth
Read MoreQuestions about whether Eli Lilly and Novo Nordisk can maintain their duopoly in weight loss drugs are fair game, but
Read More